Cure My Disease

Don't miss your cure!

 Log in / Sign up

Breath test may reveal who benefits from lung cancer immunotherapy

NCT ID NCT05985330

Recruiting now Knowledge-focused Sponsor: Centre Hospitalier Universitaire Dijon Source: ClinicalTrials.gov ↗

First seen Jul 10, 2026 · Last updated Jul 10, 2026

Summary

This study investigates whether measuring nitric oxide in a person's breath can predict how well they will respond to immunotherapy for advanced non-small cell lung cancer. Participants take a simple breath test before starting immunotherapy and again after four treatment cycles. The goal is to find a non-invasive way to identify which patients are most likely to benefit from this treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to
If breath nitric oxide levels reliably predict immunotherapy success, doctors could tailor treatment more precisely for lung cancer patients.
What could go wrong
This is a small pilot study, so results may not be conclusive. The breath test may not prove accurate enough to guide treatment decisions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC NON SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC NON SMALL CELL LUNG CANCER

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Chu Dijon Bourgogne

    RECRUITING

    Dijon, 21000, France

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.